2020 : Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: myCare-009-05.
Model (CBM) to predict therapy response and identify novel biomarkers for 5FU-based combination therapy in gastric cancer patients.
2021 : Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
Predictions of Overall Survival (OS) and Progression-Free Survival (PFS) for specific therapeutic interventions in newly diagnosed Glioblastoma Multiforme (GBM) Using Cellworks Singula™: myCare-024-04.
Cellworks Singula™ Therapy Response Index (TRI) Predicts Overall Survival (OS), Disease- Free Survival (DFS) and Tumor Regression Grade (TRG) for Oesophageal Adenocarcinoma: myCare-004
With so many payment and care organization approaches, ACOs are focused on obtaining value for their money spent. Today when an oncologist selects a therapy option for their patient, they rely on clinical trials that study large groups of patients with the same cancer. These trials are considered a success if 20-40% of patients respond to the therapy.
We look forward to meeting you and sharing the latest feedback from clinicians across the country and around the world as they seek better outcomes for their patients by adding Cellworks TRI (Therapy Response Index) to their oncology practice.
At our booth, we invite you to take the TRI Challenge, an intriguing demonstration of our precision medicine based, patient-centric approach to determining an individual patient’s response to alternative drug therapies to help clinicians select the best option first.